text:
Silk Road Medical, inc (SILK) Q3 2021 Earnings Call Transcript
By Motley Fool Transcribers – Nov 10, 2021 at 12:31AM
NASDAQ: SILK
Silk Road Medical Inc
SILK earnings call for the period ending September 30, 2021.
Image source: The Motley Fool.
Silk Road Medical, inc (SILK 2.10%)
Q3 2021 Earnings Call
Nov 9, 2021, 4:30 p.m. ET
Prepared Remarks
Call Participants
Prepared Remarks:
Good day, and thank you for standing by. Welcome to the Silk Road Medical's 2021 Third Quarter Earnings. [Operator Instructions]
I would now like to hand the conference over to your first speaker today, Marissa Bych, Investor Relations. Please go ahead.
10 stocks we like better than Silk Road Medical Inc
They just revealed what they believe are the ten best stocks for investors to buy right now... and Silk Road Medical Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of October 20, 2021
Marissa Bych -- Investor Relations
Thank you, and thank you all for joining today's call. Joining me are Erica Rogers, Chief Executive Officer; and Lucas Buchanan, Chief Financial Officer and Chief Operating Officer. Earlier today, Silk Road Medical released financial results for the three months ended September 30, 2021. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor vision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 on our business and prospects for recovery, expense management, expectations for hiring, physician training and adoption, growth in our organization and reimbursement, market opportunity, commercial and international expansion, label expansion and product pipeline development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2021. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 9, 2021. Silk Road Medical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
And with that, I will turn the call over to Erica Rogers, Chief Executive Officer.
Erica J. Rogers -- President and Chief Executive Officer
Thank you, Marissa. Good afternoon, and thank you all for joining us. I would like to start by acknowledging the immense efforts of the Silk Road team and our physician partners as we continue driving adoption of car forward against the headwinds of the COVID-19 pandemic. The third quarter was a difficult period for the U.S. hospital system and specifically for elective inpatient procedures like TCAR. As we signaled in mid-September, the COVID-19 Delta variant drove capacity constraints, staffing shortages and overall disruption in a significant percentage of hospitals across our sales regions. Despite these challenges, we recognized $24.7 million in revenue for the quarter, reflecting 23% year-over-year growth. The pandemic and its consequences have created a more complex environment and a greater impact to our business than we had expected back in July, which carried over from Q3 into Q4. As a result of these dynamics, we are revising our 2021 revenue guidance to a range of $99 million to $102 million. Lucas will discuss our full results and provide more commentary on our financial outlook shortly. As we look at our business, we are confident that the headwinds we have been facing are overwhelmingly pandemic related and in our view, transient. In regions where vaccination rates are high, and hospitals have capacity, patients are presenting, and we are executing on our strategy. In fact, despite COVID hospitalization soaring during the recent Delta wave, the total number of physicians performing a TCAR in Q3 was in line with Q2. Even in the hardest hit areas of the country, trained physicians continue to perform TCAR, albeit fewer procedures. Our regional utilization data also allows us to analyze the relationship between TCAR procedures and COVID hospitalizations across specific parts of the country.
This analysis shows a stark contrast between the rate of procedures in less impacted versus harder-hit regions during the third quarter. For example, in Southern and Midwestern regions, both heavily impacted by the Delta variant, procedures per physician fell roughly 13% in Q3 versus Q2. In the Northeast, Mid-Atlantic and Western regions, areas with higher vaccination rates and fewer hospitalizations, procedures per physician grew roughly 10%. In totality, this analysis offers an encouraging view of the performance of our business and the prospects for future growth as the pandemic wanes. On our last call, we said that our business was back on offense. And today, we remain just as excited about our underlying opportunity for growth and penetration over the coming year as we did three months ago. We are hopeful for a future in which COVID-19 is endemic and managed without the severe spikes in hospitalizations that we have seen over the last 18 months. As of now, and as we have throughout the pandemic, we are investing confidently in the people and programs that will drive our growth in 2022 and beyond. We remain as committed as ever to establishing TCAR as the new standard of care in carotid artery disease. With that, our number one strategic priority for 2021 is U.S. commercial execution. Today, we are pleased to announce that we are on track to exceed our goal of training at least 200 new physicians by the end of the year. We are also on track to exceed our territory expansion target of at least 50 sales territories by the end of the year. Importantly, as measured by time from training, procedures per physician continues to grow overall and across each utilization quartile despite continued growth in the denominator of trained physicians. This remains true even against the pandemic dampening effects on carotid diagnoses and procedures and the overall healthcare system. We are actively building relationships across physicians and hospitals to bring to fruition the long-term value of TCAR, a value unshaken by COVID, and we are reducing the risk of stroke and its devastating impact for patients every single day.
We remain well positioned to increase our procedural share versus CEA given expansion of field team, initiatives to drive physicians up the adoption curve, physician training programs and the continually growing base of clinical evidence for TCAR. Moving on to our second strategic priority for the year, preparing for standard surgical risk expansion. At the 2021 Vascular Annual Meeting in August, an independent propensity matched analysis in over 20,000 standard surgical risk patients illustrated equivalent risk of perioperative stroke, death or MI, plus ipsilateral stroke through one year in CEA versus TCAR. With cranial nerve injury risk significantly reduced with TCAR. Conclusions of the study were clearly outlined, TCAR should be expanded for use in standard surgical risk patients. The study affirms what we already understand at Silk Road, safely preventing stroke while delivering benefits from a less invasive approach is possible across a broad range of patients, anatomies and disease morphologies. TCAR's clinical and patient satisfaction benefits paired with its proven efficiencies over CEA, give us confidence in driving adoption and advancing our impact on the lives of patients at risk for stroke due to carotid artery disease over the long term. Importantly, we are making progress toward receiving FDA approval to expand indications for TCAR into the standard surgical risk patient population. And over, the FDA requested that we provide them with additional data. We have since submitted that additional information as an amendment, and we believe that we are still on track to receive an FDA decision by the second quarter of 2022. Our teams and the physician community remain enthusiastic about the opportunity for standard surgical risk label expansion, bringing TCAR to a level-playing field with CEA, and we continue to prepare for commercial launch. This includes planning for a post-market study, engaging with CMS on reimbursement coverage, supply chain preparation and augmenting our training and marketing programs and materials.
Regarding our additional long-term growth drivers. We continue to make progress on objectives to introduce new and improved TCAR products, expand into international markets and innovate new transcarotid therapies in neurovascular and carotid disease states -- cardiac disease states, excuse me. For example, we are active in site initiation processes for our neuroprotection in transcarotid embolectomy or night one feasibility study. Our R&D head count, programs and capabilities continue to grow. We remain committed to expanding and deepening our significant lead in developing the TCAR market in the U.S. with numerous product and clinical initiatives while working to unlock the $5.1 billion TAM associated with exporting TCAR globally. We expect to provide further updates on many of these initiatives on our future earnings calls. In closing, we were surprised by the speed and the severity with which the Delta variant impacted the U.S. hospital system in Q3. And we acknowledge that our second half revenue results will reflect the challenges in our operating environment. However, we are encouraged by the fundamentals of our business as the environment begins to clear. As we sit here today, we are seeing early signs of improvement, which we continue to closely monitor. We also intend to remain transparent regarding the ongoing pandemic and its impact to our expectations. We are incredibly proud of Silk Road's response to the challenges posed by COVID and our excitement for the opportunity to reaccelerate into 2022 remains unhindered. Most importantly, our dedication to the long-term value of TCAR for patients and hospitals alike remains stronger than ever.
With that, I will now turn the call over to Lucas Buchanan, our Chief Financial Officer and Chief Operating Officer.
Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer
Thank you, Erica. Revenue for the three months ended September 30, 2021, was $24.7 million, a 23% increase from $20.1 million in the same period of the prior year. The number of TCAR procedures in the quarter was just shy of 3,400, a 20% increase from the same period of the prior year. Year-over-year growth was driven by increased adoption of TCAR across an expanded base of hospital accounts, trained physicians and active sales territories, despite the more constrained environment due to the Delta variant impact in the third quarter of 2021 as compared to the same period of 2020. Gross margin for the third quarter of 2021 was 75% compared to 73% in the third quarter of the prior year. Gross margin in the prior year period included unfavorable production variances as a result of temporarily idled manufacturing operations and lower-than-anticipated demand due to COVID-19. Total operating expenses for the third quarter of 2021 were $31.9 million, a 33% increase from $23.9 million in the third quarter of 2020. R&D expenses for the third quarter of 2021 were $6.9 million compared to $4.7 million in the third quarter of 2020. The increase in R&D expenses was driven by growth in personnel and investment in new and ongoing R&D programs. Sales, general and administrative expenses for the third quarter of 2021 were $25 million compared to $19.2 million in the third quarter of 2020. The increase was due to the continued expansion of our sales team and commercial efforts and general corporate and other costs associated with operating as a public company. Net loss for the third quarter was $13.9 million, equating to a loss of $0.40 per share as compared to a net loss of $10.3 million or a loss of $0.31 per share for the same period of the prior year.
We ended the quarter with $122.8 million of cash, cash equivalents and short-term investments. As Erica mentioned, our updated revenue expectations for 2021 are in the range of $99 million to $102 million. Although U.S. COVID hospitalizations have been steadily declining since early September, the Delta wave is receding more slowly than the late 2020 to early '21 winter wave. Today, we are encouraged that COVID-19 hospitalizations and the rate of community spread is quite low in some of the regions of the country that were the hardest hit in Q3. But there are still almost 47,000 patients hospitalized with COVID across the country with hospitalization still rising in 12 states and cases still rising in 23 states. Delta continues to move. Staffing issues remain as frontline workers seek higher paying jobs and feelings of burnout persist. These phenomena, in turn, drive competition among physicians and therapies for scarce OR time and staffed inpatient beds. All of these factors inform our revised guidance, and it goes without saying there is continued uncertainty around the future course of the pandemic in patient behavior. All said, we are holding our own and continuing to expand our presence in this environment. As a reminder, our 2021 revenue guidance does not assume any contribution from a standard surgical risk label expansion.
At this point, I'd like to turn the call back to Erica for closing comments.
Thank you, Lucas. We are very pleased with our strong year-to-date performance despite the headwinds associated with the Delta variant. And we are confident that Silk Road remains well positioned for strong growth into 2022 and beyond. Our teams remain dedicated to meaningfully impacting both stroke prevention and acute stroke treatment. And we know that our impact will continue to grow as the pandemic disruption subsides. And speaking of our team, I want to highlight our recent in-person national sales meeting, which we held in September after multiple delays. This year's meeting carried more meaning than prior years with our people bringing an unparalleled enthusiasm to our three-day event following a very long period pandemic-driven separation. It was not only an opportunity to organize and emphasize our goals around physician adoption. It was also an opportunity to unify a team fighting for a better standard of care. The energy and sense of purpose was palpable across the organization and emphasized that human capital is Silk Road's strongest asset. In addition, just two weeks ago, our teams honored World Stroke Day taking pride in the efforts of Silk Road and improving awareness and more importantly, preventing stroke and its horrible ramifications for patients and their families. We are confident in the continued growth and development of our commercial team as we recognize the enormous market potential for TCAR and the associated career opportunities for those who seek to make a difference. As we move toward the end of 2021, we are encouraged by early signs of recovery from Delta variant and more importantly, Silk Road's long-term value proposition. We continue in our persistence to improve patient outcomes and remain committed to new therapies across new indications in the years ahead.
With that, we will now open it up to questions. Joining me and Lucas Buchanan today for the question-and-answer portion of the call is our Chief Commercial Officer, Andy Davis. Operator?
[Operator Instructions] Our first question comes from the line of Robbie Marcus from JPMorgan.
Lilia-Celine Breton Lozada -- JPMorgan -- Analyst
Hi. This is actually Lili on for Robbie. Thanks for taking the question. I know it's still early, but I was hoping you could share some early thoughts on 2022. Do you think where the Street is sitting right now at $145 million is a reasonable place to be right now for next year? Any color you could share there would be helpful.
Lili, I'll take that one. We're not providing 2022 guidance today. I think the takeaway as we continue -- as we have throughout the pandemic to invest in the key inputs of our business, namely opening new hospital accounts, training physicians and expanding our sales team, and that all drives future growth. And so we provided some color on our progress on those fronts that we think set us up well for the future.
Got it. That's fair. And just a quick follow-up on standard risk. Is there any way you can quantify to what extent you've been treating standard risk patients right now before formally getting it on label. Is 15% to 25% of procedure is a fair assumption?
Lili, I'll take that one. We have not provided any quantification. I think this question is probably borne out of the fact that there were a fair number of patients presented in some data at the Vascular Annual Meeting back in August. And I think the way to explain that is that the definition the authors used for standard surgical risk was slightly different than other definitions of standard risk and namely in the age cutoff, which provided a big area of overlap in patients. And so the best way to think about it, Lili, is that -- there's no sort of black and white in the eyes of a physician on standard surgical risk versus high risk. There are degrees of risk in the interpretation of physicians. Clearly, the company sticks to our approved and labeled indication, which is high surgical risk.
Got it. That's helpful, thanks again.
Our next question comes from the line of Rick Wise from Stifel.
Rick Wise -- Stifel -- Analyst
Hi, good afternoon to you both. Erica, back to -- hard not to start with COVID again. You said very specifically you're seeing early signs of improvement. I want to make sure I really understood exactly what you're saying. You're saying and since the start of the fourth quarter, last week, over the last few weeks, and you give us a beautiful breakdown by region and tiers and everything, but is it retail? Is it across the board? How do we think about that statement and reflecting on the new guidance for the fourth quarter, especially?
Yes. Let me take part of that for you, Rick, and thanks for joining us today. So I mean, really simply put, TCAR is right in the crosshairs of the Delta variant. And we saw real impacts in certain regions that are less vaccinated that led to obviously higher hospitalizations. I do want to remind everyone that we are a U.S.-only business that is inpatient, right? And majority elective when you think about the mix of asymptomatic versus symptomatic. And so we were right in those crosshairs of the hardest-hit areas of the Delta variant, which turned out to be the South and the Midwest, as we said in our prepared remarks. As it relates to the quarter, I think it's safe to say that the recovery from Delta variant has been slower than what we saw in the winter wave. The sort of bounce back that we saw coming out of the first quarter. It has not been like that with the Delta variant. And as we said in our prepared remarks, it even spilled over into October into this quarter. Now sitting here today in November, we like what we're seeing in the past really a few parts of the early part of November. But I think it's safe to say that Delta extended into October.
Yes. That makes sense. I didn't know what -- Lucas, do you want to say something or should I go ahead?
Yes, I can add a little color. I mean, again, kind of as COVID hospitalizations go, so does TCAR procedures for better or for worse, depending on whether the hospitalizations are going up or going down. And so with that, the monthly procedure volume has improved from September over August and October over September. And as Erica mentioned, November is trending well. So it kind of matches curve, so to say.
Got you. Turning back to the topic of label expansion. I mean it's encouraging, obviously that FDA asked you were able to submit, that sounds great. But unless I'm misremembering, Erica, I think your prior public statements were you were hoping for late '21, early '22. And if I heard you correctly, tonight, you're saying 2Q '21, is that understandable conservatism given everything that's happening in the world? Is it that the request for data still slowed things down -- Or how do we think about that if I -- my memory is correct here.
Yes. No. I mean, it's simple. We are still within the timing expectation that we set forth. Sitting here on November 9. Obviously, we're running out of days in the quarter, but the realm of options is still what we stated in the beginning.
Okay. So no change there. Great. Okay. And maybe last for me, and maybe this is more for Lucas or whoever. The unusually high SG&A spend this quarter. I think it's the highest dollar number. I've seen $25 million up sequentially a few million. And you sort of said it right up front, it's in the press release, you're investing in multiple ways, expansion of teams, commercial efforts, etc. But maybe help us understand for that unusual spend this is getting ready for standard risk? Is this international preparedness? Is this open the new hospitals? Help us understand and where do we go from here with that dollar?
I think that's quite simple as well, Rick, and it really comes down to primarily the U.S. commercial effort and investing in the expansion in territories, which we've said all along that our goal for this year was to be in excess of 50 territories, and Erica mentioned, we expect to exceed that on our way at roughly 75 by the end of next year, which is really the coverage model that we think really covers the bulk of the market in terms of the hospitals and docs that we want to train and market to and drive their adoption curve. So some of it is timing with respect to -- it's not a linear growth pattern in terms of the commercial head count and in Q4 was a little heavier than prior quarters. And I think, again, the key takeaway here is we continue to invest confidently because the fundamentals of the business are strong when you strip out the COVID impacts.
Yes. And truly congratulations on a very solid quarter, and I know it's a challenging time, but -- so it's great to see it. Thank you.
Our next question comes from the line of Adam Maeder from Piper Sandler.
Adam Maeder -- Piper Sandler -- Analyst
Hi, guys. I appreciate you taking the questions here, and congrats on the progress. I wanted to start on standard surgical risk and maybe just ask for any kind of new updates or line of thinking around reimbursement and then post-market approval study. I mean I think you touched on both of those briefly in the prepared remarks. But wondering if the expectation is that reimbursement will come in tandem with FDA approval or subsequent to? And then I was wondering if you could kind of flesh out how you think about the post market study that will likely coincide with standard surgical risk. And then I had a follow-up.
Sure. Adam, thanks for joining us. So in terms of CMS coverage, as we've said all along, we've kind of been in lockstep conversation with CMS and FDA and the Society of Vascular Surgery at really every step of the way on -- since the dawn of time, but even more specifically here on standard surgical risk. And so typically, the coverage specifics won't be worked out until the actual approval is in hand. But the conversations have begun. So it will happen one after the other, but we expect it to be an efficient process with CMS. As it relates to a post-market study, we are kind of following what has happened historically with carotid artery stent approvals or label expansions, which is they typically are accompanied with a post-market requirement -- post-market study requirement. And so we are planning, as such, which means that we're doing the work of figuring out what a protocol might look like, what the sites might look like, who the PIs might be, all of those kinds of things, just getting in the ready position.
Got it. That's helpful, Erica. And then for the follow-up, just switching over to the international go-to-market initiatives that you're in progress with. Just anything more that you can share on China and Japan, the progress that you're making in those geographies and potential time lines? And curious if there's updates on things like reimbursement or infrastructure. And I guess the big question I'm really just trying to better understand is if we should think about 2023 as a reasonable base case for international revenue contribution if it's '24, etc. So if you could help orient us there, that would be great.
Yes. So we continue to make progress in the quarter on both China and Japan. Right now, it's really all about the regulatory effort, which does dovetail with the coverage and reimbursement efforts in those countries as well. So they're not really as distinct processes, all of it wheels in motion right now did make good progress in the quarter. I think we also talked about on our last call that we've been engaging with potential commercial partners, which is to say that we're likely to partner with somebody already in those geographies versus kind of propping up our own direct organization in either of those two countries. And those conversations have also moved forward in the quarter. As it relates to timing of commercialization, Adam, we just haven't given any specifics there yet. I know that's not a super satisfactory answer, but when we have more meat on the bones on precise regulatory outcomes. I think at that point, we can begin to talk about timing.
Okay, understood, understood. Thanks for taking the questions.
Yeah. And then we get Gregory.
Our next question comes from the line of Danielle Antalffy from SVB Leerink.
Danielle Antalffy -- SVB Leerink -- Analyst
Hi, good afternoon guys. Thanks so much for taking the question. Just one follow-up question on the data filing for Standard Risk, Erica. If you could give any color on sort of what the new data update might have been that you filed? Or how to think about this an entirely new data set? Is it just incremental data or another cut of the data that you already filed? And then I have one follow-up just on the quarterly results.
Sure, Danielle. Thanks so much for joining us. So typical of PMAs, there's been a lot of back and forth with the FDA kind of all along, even prior to the submission itself and since the submission. And so we got a question from FDA and upon clarifying what that question meant. We basically did a kind of subset analysis of existing data, is the way to think about it.
Okay. Got it. That's helpful. And then as it relates to the quarter, I don't know if you guys even track it this even track it this way, but the COVID -- is there a way to quantify -- you gave some numbers that were very helpful about like growth in regions that weren't significantly impacted by COVID. But can you quantify like a dollar value from COVID? And if not, maybe even some color on sort of where we are in the referral funnel if you have visibility into that and sort of cancel how many procedures that are not asymptomatic have been canceled. Anything to give some color on sort of what the impact was would be super helpful.
Yes. Let me take the first half of that, and I'll pass it over to Andy for the second half. The one thing Erica mentioned is that a disproportionate share of our procedures and therefore, revenue comes from states and regions where cardiovascular disease is -- risk factors are high and disease burden is high, which also correlates with area in the country that are less vaccinated and have higher hospitalization rates. So that's part of it. And again, we did an analysis year-to-date looking regression analysis, looking at COVID hospitalizations as the input nationally in TCAR procedures is the output, and it's incredibly statistically significant and explains most of the variation in procedures. And so again, that gives us confidence, coupled with the data from less-hit regions and the fundamentals there that this is at least transient with the current aspects of the pandemic. We'll see what the future holds. Obviously, we're all hopeful for an endemic management and new antivirals and more vaccination and kids getting vaccinated and all those things into 2022, but we're also less and less in the business of predicting where COVID goes. I'll turn it over to Andy for the other half of the question.
Andrew S. Davis -- Chief Commercial Officer
Sure. I'll address the funnel impact on the patient pipeline, and we remain very optimistic that patient behavior is continuing to improve as the COVID Delta variant lifts. They're going back to the doctors. They're being diagnosed. They're being put into the queue to be treated. So we have seen a dramatic increase in that behavior, which is good, and that's in the recent weeks. More importantly, as the Delta variant really hit us throughout the August, September, October time frame, we do to our best ability, track patients that were in the queue where procedures are being canceled and/or delayed. So we're working very closely with our physicians to find those patients and get them back into the queue to be treated. So we monitor and measure that very closely. So we feel like we're going to be able to capture a fair amount of those patients that were on the sidelines as the hospitalizations and capacity really impacted our ability to treat them. So we feel optimistic. The fundamentals are still intact. And I'm bullish on the days ahead.
Thanks for the color.
Thanks Danielle.
Our next question comes from the line of Joanne Wuensch from Citi.
Joanne Wuensch -- Citi -- Analyst
Good afternoon. Can you hear me OK?
Yes, we can. Joanne. Thanks for joining us.
Hi, thank you for taking the question. I'm curious on your last question. Have you started to think about how the backlog is building, so that when the physicians and the patients sort of feel more comfortable about getting back into the operating room, they can do so.
Yes. I think there's a two-part answer to that, Joanne. I mean as Andy just said, the business of healthcare is starting to return, again. This is the second go-round of recovery this year, as you know. But it is starting to return, patients are back in the funnel in these hard-hit regions that we've been describing. So that's a very positive trend here. I think the other thing that we have to talk about out loud is this staffing shortage issue, which we mentioned in our prepared remarks, it is very real. Andy and his team are experiencing this every day to the extent that we're doing procedures on the weekends because they can't get them scheduled during the week. And so what that has created is this competitive environment for OR space and people and staffed beds, regular hospital beds and ICU beds alike. And so all of these elective-type procedures, even the urgent elective, which is the category that we're in are fighting for resources, quite frankly, in some of these very hard-hit areas. And in fact, there's an anecdote that we just heard the other day that the National Guard is being called into the Pacific Northwest to help staff hospitals. So it is still quite channeling from a staffing perspective.
I'll ask -- I'm sorry, go ahead. I'm sorry, go ahead.
No, no, go ahead.
Was just going to add -- I was going to add that it's a really interesting conundrum because we had many, many days and months where there weren't enough beds to treat patients. Now there are enough beds, but not enough people to support the patient flow. So it's one problem is fixed and another problem we had. But we're working to it.
I was just looking for -- if there was a way to quantify the backlog that's building -- and there may not be, but I was just curious about that.
Well, in prior periods, Joanne, the backlog cleared quite quickly, but in prior periods, we weren't dealing with as much of a staffing issue. So it's a little bit harder to say as we sit here today. Obviously, the wave itself is receding slightly more slowly, and there's different variables at play. But again, in prior times, the backlog cleared quite quickly because these patients are at risk for stroke. And once the decision has been made to treat, it's not made lightly as we've always talked about. So they do want to get these patients treated as soon as they can. There is some yield loss to patients that don't come back for whatever reason. But as Andy said, the team is working hard to help make sure that we're doing everything we can to bring patients back.
That clarification is helpful. And then my second question really has to do with the timing of some of the other efforts that you've unveiled outside of TCAR, should we be looking for announcements of that like in the coming quarters or at least maybe in 2022?
Yes. I think some of the things that we talked about in the prepared remarks, for example, the NIGHT one study, the neuroprotection in transcarotid embolectomy study. We're making good progress on site initiations and getting those sites ready to enroll. So we're hopeful that there'll be some further discussion about that trial in future earnings calls coming up.
Terrific, thank you so much for taking my questions.
That concludes the Q&A session. I will now turn the call over to Erica Rogers for closing remarks.
Thank you all for your time and attention today.
Call participants:
More SILK analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
SILK ROAD MEDICAL INC (SILK) Q1 2021 Earnings Call Transcript
Don't Panic: Social Security Payments Could Continue Even in an Unlikely Debt Default


TAMPA, FL (Oct. 13, 2008) - A team of pharmacy students from the University of Arizona College of Pharmacy was named the winner of the National Community Pharmacists Association's (NCPA) 2008 Pruitt-Schutte Student Business Plan Competition. A team from the Samford University McWhorten School of Pharmacy came in second, and a team representing the University of Kansas finished third.
"With each passing year the level of interest in independent community pharmacies grows among students" said Stephen L. Giroux, RPh, NCPA President and an upstate New York pharmacy owner. "Every team of students who participates in the Pruitt-Schutte Student Business Competition are winners with a better understanding of the entrepreneurial side of pharmacy. Yet three teams standout: the winner, University of Arizona; the runner-up, Samford University; and the third place finisher, University of Kansas; who each submitted outstanding business plans."
The Pruitt-Schutte Student Business Plan Competition is the first national competition of its kind in the pharmacy profession and is named to honor two champions of independent community pharmacy, the late Neil Pruitt Sr. and H. Joseph Schutte. The competition is supported by the Pruitt and Schutte families, the NCPA Foundation, and Covidien (formerly Mallinckrodt Pharmaceuticals). This is the fifth year the competition has been held. This year's competition drew entries from 30 schools and colleges of pharmacy-nearly one-third of all U.S. pharmacy schools.
The three finalist teams and advisors made live presentations of their business plans before the competition judges and an audience during the annual convention after receiving complimentary registration, travel, and lodging Giroux announced the results of the competition during the Opening General Session and the teams were honored at the NCPA Foundation's Award Ceremony.
"The NCPA Foundation is focused on preserving the legacy of independent community pharmacies, and what better way to ensure that outcome than to sponsor a competition that teaches pharmacy students about ownership," said Sharlea Leatherwood, PD, NCPA Foundation President. "The plans the winning three teams submitted were truly excellent roadmaps to success."
Team members from the University of Arizona were Lauren Bartoli (captain), David Jacobson, Mai Huong Nguyen and Katherine Schiraldi. Kevin Boesen was the team's advisor. Their chapter received $3,000 and $3,000 was contributed to the school in the dean's name to promote independent pharmacy. The team members, team advisor, and the dean also received complimentary registration, travel, and lodging to NCPA's 2009 Multiple Locations Conference.
Team members from Samford University were Alexander Sproule (captain), Christy Garmon, Brad Nail and Elizabeth Redmill. Condit Steil was the team's advisor. Their chapter received $2,000 and $2,000 was contributed to the school in the dean's name to promote independent pharmacy.
Team members from Kansas University were Eric Gourley (captain) and Melissa Rufenacht. (Dennis Grauer was the team's advisor. Their chapter received $1,000 and $1,000 was contributed to the school in the dean's name to promote independent pharmacy.
There was a tie amongst the finalists, so the remaining eight teams received $300 dollars for each person from the school who registered for the convention. Those teams for Ohio Northern University, University at Buffalo School of Pharmacy, University of Georgia, University of Oklahoma College of Pharmacy, University of Southern California School of Pharmacy, Virginia Commonwealth University, Washington State University, and Western University of Health Sciences School of Pharmacy. All participating schools receive a plaque commemorating their participation in the competition. Each year, competing schools receive an engraved plate to add to their plaque, and teams placing in the top 10 receive a special plate acknowledging this distinction.
Judges for the written portion of this year's competition were: Dirk White, R.Ph, White's Pharmacy; Donald Moore, RPh, Moore Drugs; Dave Creecy, RPh, Poquoson Pharmacy; and Hamid Mohaghegh, RPh, Family Pharmacy Inc; Stephanie Smith Cooney, RPh, Gatti Pharmacy; David Smith, RPh Means-Lauf Super Drug; Richard Moon, RPh, Pharmacy Innovations; Joseph Harmison, PD, Harmison Pharmacies; Justin Wilson, PharmD, Valu Med Pharmacy; Dorinda Martin, RPh, Dripping Springs Pharmacy; Keith Hodges, RPh, Gloucester Pharmacy; Cheryl Garvin, RPh, Leesburg Pharmacy, Inc., Diana Courtney, RPh, Lake Shore Pharmacy, Donnie Calhoun, RPh, Golden Springs Pharmacy; Donald Moore, PD.
The judges for this year's live competition were: Sharlea Leatherwood, RPh, NCPA Foundation President; Calvin Anthony, PD, Tiger Drug; Edward Berg, MBA, CPA, CPCU, Pharmacists Mutual Insurance Company; Larry Doud, Rochester Drug Cooperative, Inc.; James L. Grigg, AmerisourceBergen; Stephen Mullenix, RPh, Covidien/Mallinckrodt Pharmaceuticals; Jim Springer, McKesson Corporation; Dan Strause, CPA, Defortest Pharmacy; John Tilley, PD, Immediate Past NCPA President, Zweber Apothecary.
The Foundation has received a challenge grant pledge from Pharmacists Mutual Insurance Company (PMIC) for $250,000. The challenge grant from the Competition's second major corporate sponsor will support the NCPA Foundation Pruitt-Schutte Business Plan Competition Endowment Fund. As a result the Foundation is seeking contributions to realize the full benefit of PMIC's pledge and to double a donor's contribution.


I-O Data, a Japanese computer peripheral manufacturer, has recently announced its latest HDPC-U series of hard disk drive lineup, which includes three different colors and higher storage capacity of 750GB hard disk models. It is about 160 grams of the whole body weight.
HDPC-U series is a simple portable hard drives with thin square, light-weight and easy to carry. It has business card holder and its 14mm thick of compact body size can easily fits into the palm or any briefcase.
This new series of hard disk drives come with square body design and rubber at the bottom, so the hard drives can be put on any surface with non-slip effect. Also the hard drives' cases are designed with beautiful gloss finish and scratch-resistant materials to protect the hard drives from damaging the surface or accidentally drop.
I-O Data's HDPC-U Series hard drives are equipped with USB Mini port; support DOS/V to handle double-byte Japanese text; compatible with Windows (32/ 64-bits) and Apple Macintosh Machine. There is a blue LED at the side of the case to indicate the activities or in-use of the hard drive.
They will be available in three colors, which are Piano Black, Pearl White and Bitter Brown. The I-O Data 750GB models will soon available for 13,600 Yen or about of $165.72.


They will shine bright like a diamond when you present them with this playful advertising specialty!
Every customer and employee can be a star with this advertising specialty!
Make a fresh brand statement by giving customers this tin-and-candy combo.
Give customers a fresh look at your logo with this thoughtful gift.
Attract customers with this refreshing new take on business cards.
Give customers a refresher on your brand with this jar of mints.
Freshen up your promotional campaign with our custom thumbs up mint card!
Make your cause even greater and raise awareness with this advertising specialty!


This question is about creative design.
Read the Design Brief and your Specification very carefully. Sketch five designs that are suitable for a storage unit, to hold valuables such as jewellery or computer games. Each storage unit must be based on the Mackintosh design criteria.


Great space in the heart of Cincinnati's OTR! Stay among the city's hottest restaurants, bars and shops! Just a 10 minute walk to Horseshoe Casino or Fountain Square. Just a 15 minute walk to Great American Ballpark or the Convention Center.
Cincinnati, Ohio · Član od kolovoz 2014.


Police and their unions continue to demonstrate their racism and propensity to abuse their authority. In response to Miami Dolphins Kenny Stills, Alfred Wilson, and Robert Quinn demonstrating during the national anthem, the Palm Beach County PBA has encouraged its members to either seek a refund of previously purchased tickets or not purchase any tickets at all. Apparently discounts were going to be offered to union members because the Dolphins planned to honor first responders, and the PBA assumed this also meant that players would be forced to stand for the anthem. It is not clear from whence the PBA obtained this belief, but it is as ridiculous as it is illogical. Stephen Ross had backtracked on his off season comments about making players stand, and the Dolphin's hastily retracted leaked disciplinary conduct policy has not gone into effect. It continues to amaze how invested white men are in these displays of dominance and control over Black men. Black people who refuse to engage in subservient deference to whites often find themselves on the receiving end of these kinds of petty, spiteful, immature acts. Kenny Stills of the Miami Dolphins appears to be leading the way as the main voice regarding the protests this year as the two previous years' leaders–Colin Kaepernick and Eric Reid–remain blackballed. A fact that Stills has made a core basis of this decision to continue his protest.
Article below by Mike Brehm.
South Florida police unions are urging their members to not buy Miami Dolphins tickets or seek a refund because several players had protested during the national anthem before the preseason opener.


text:
Magnolia Nabs Ireland's Oscar Entry 'Viva,' Plans 2016 Release
CREDIT: Courtesy of Treasure Entertainment
Magnolia Pictures has nabbed North American rights to the coming-of-age drama "Viva."
The film is set in Cuba and centers on a gay hairdresser who tries to reconcile with his estranged father while launching a career as a drag performer. Magnolia is eyeing a theatrical release in 2016.
"Viva" is directed by Paddy Breathnach ("Man About Dog") and is executive produced by Benicio Del Toro. It premiered to strong reviews at the Telluride Film Festival and will be Ireland's official entry for the foreign-language Academy Award competition.
The deal was negotiated by Magnolia Senior VP of Acquisitions Dori Begley and Magnolia VP of Acquisitions John Von Thaden, and by Josh Braun of Submarine and Nate Bolotin of XYZ Films on behalf of the filmmakers.

redpajama_set_name: RedPajamaCommonCrawl


The procedure necessary for American candidates wishing to obtain a visa (also knows as the Schengen Visa) to stay in Spain for longer than 90 days used to be a straight forward process which could easily be done while in the country. However, it is now a little more complicated, especially as each Embassy and Consulate handles things differently. Please note that for our program, if you choose to get a visa, then you will be applying for a STUDENT VISA.
Adelante accepts candidates of all nationalities – however, you are responsible for finding out the visa requirements.
It is necessary for you to obtain your student visa before you leave the States. It is not possible to get your visa once in Spain and you can't have it sent on to you. The visa, once issued, is fixed in your passport. In most cases, your passport must be valid for six months after your program ends. If you are in need of a new passport or have to renew your existing one, please visit the U.S. State Department website.
Visas are basically permits that enable you to be in a specific country for more than 90 days. Adelante will happily guide you through the visa process and do anything we can to help you understand the visa process. The process for obtaining your visa can take some time, so be prepared to apply for the Adelante program well ahead of time. As a general rule, if you know you will be pursuing the visa process, you should aim to apply for the visa at least 2 months ahead of your departure date. Consulates will accept your paperwork no later than 45 days prior to your departure date. Most of the Consulates now require you to apply in person, so you also need to take this into account if your Consulate is some distance from you.
The first step in applying for your visa is to contact the Consulate that has jurisdiction over the State in which you live or where your permanent address is. This can be difficult – we have found that fax may work best, since often times opening hours are just 9 – 12!.
Most Consulates require you to make an appointment to submit your documents, be sure to check this in advance.
Click here for a list of Spanish consulates and their jurisdictions.
The documentation required for your application will vary with each Consulate so check the exact requirements with them. The list below will act as a guide to the documents you may need to provide.
A completed visa application form plus three photocopies. Click here for details on how to apply and a link to the Schengen Visa Application.
Passport, plus 1 copy, valid for a minimum of 6 months. Your passport must be signed and must have a blank page to affix the visa.
4 recent color passport-size photos.
Original and 1 copy of the Acceptance letter from Adelante addressed to the Consulate General, verifying full-time enrollment in an official University or School abroad. This should include verification of full payment of tuition, room, board, and full medical insurance coverage for the length of the program.
Original and 1 copy of the letter of acceptance as a full time participant from the University or academic institution abroad. This letter must indicate the address of the center, specific dates and number of hours per week, type and level of the studies to be completed. Proof of available accommodation abroad, such as letter of invitation from the hosting family, University dorm reservation, etc.
Verification of financial support: notarized letter from the student's parents explaining financial responsibility for the student while abroad (at least $350 per month of stay), copy of their last bank statements, and photocopy of the student's parents last Income Tax Return (pages 1 & 2 of the 1040 form).
Original letter on doctor's letterhead and 1 photocopy, verifying that the student is in good physical and mental health, free from any contagious or infectious diseases and drug addictions.
Airline tickets to and from Spain plus 1 photocopy. If the airline just provides e-tickets, proof of payment is necessary (i.e. credit card statement).
Cash or money order only in the amount of $100 for visa fee (US citizens). This fee must be satisfied in the exact amount and is not refundable.
If you do not wish to go to collect your passport and visa in person, and your Consulate allows this, then you can arrange for it to be sent to you. This may mean providing a pre-paid US Postal Service Express Mail-Overnight envelope. Again, check this with your Consulate.
For more information on student visas and Spanish Consulates in the USA, go to the Spanish Embassy website.
Please note that even though you obtain a student visa prior to departure, you will still be required to report to the nearest police station to your program abroad. You must do this within the first 90 days in the country. There, they will examine your visa and stamp it or give you other documentation showing you may stay up to the 6 months shown on your student visa. Because there have been so many changes recently, often the advice you receive from your Embassy or Consulate here will not coincide with what the police department abroad tells you. This is not a big deal, just be prepared for a variety of different procedures both here and abroad should you opt to obtain a student visa.


Established in 1980 by Managing Director Christopher McCormick along with his wife Pearl, we are an independent supplier of quality sourced produce specialising in rare breed and dry aging across beef, pork and lamb. We have been in the industry for over 30 years, and from this gained extensive knowledge into the trends and desires of our chefs. We aim to provide a service that we are proud to have our family name tied too. We maintain a very personal relationship with our customers, and are available to them night and day allowing a truly connected partnership and them to be supported by us for any needs they may require.
At C&P we are focused on sustainable purchasing, in doing so we move with seasonal produce to reflect what is required in the kitchen to offer products at there peak.
To achieve and maintain the highest levels and standards in all aspects of the business in a very highly competitive market.
Our customer base is extensive and diverse, and encompasses major corporate groups, independent catering companies and individual sites.
As a company we are totally committed to provide a first class service, the finest quality, the keenest prices while still maintaining the highest levels of 'Food Safety'.
To ensure our 'Food Safety' standards are achieved and maintained, we have adopted the formalised approach, based on EFSIS (European Food Safety Inspection Service). To enable us to maintain this high level of 'Food Safety Law Compliance', we constantly receive the latest information on directives, etc. from the Meat & Livestock Commission, S.O.F.H.T. (Society of Food Hygiene Technologists) and from our local E.H.O's.
All our products are produced to the Meat Buyers Guide specifications unless otherwise requested. Our meat products are sourced from Scotland, England, Ireland and Wales, all beef is aged for a minimum of 3 weeks or longer if required. Imported ranges can be supplied if required. We are a certified member of the Guild of Scotch Quality Meat Suppliers and an approved stockist of specially selected Scotch Lamb.


text:
'I was too scared to leave my hotel room': Why Cecchin is retiring from NRL
NRL 2021
By Andrew Webster
August 31, 2021 — 6.00am
Leading referee Matt Cecchin will retire at the end of this season — and most likely this weekend — after revealing a decision against Cronulla two weeks ago left him "scared to leave my hotel room".
Regarded by many as the game's best whistleblower, Cecchin says a crisis in confidence in himself as well as missing out on the headline matches has prompted his decision.
The 48-year-old said he had been contemplating retirement for months, but the tipping point was a call against the Sharks against the Knights in round 22.
With 10 minutes remaining, and the scores locked at 14-all, Cecchin penalised Sharks defenders for carrying Knights centre Bradman Best from the field of play into the in-goal after calling "held".
It was a 50-50 call, although Sharks coach Josh Hannay criticised the decision afterwards. Cecchin and his partner, Brent, were staying at the same hotel.
"I didn't leave my hotel room because I was scared," Cecchin told the Herald. "Not because I felt threatened, but I wanted to prevent any incident that could make it a drama. Nobody gave me that feeling, but I didn't want someone to make a comment in a lift or the foyer.
Top referee Matt Cecchin is retiring from the NRL ... and this time it's for good. Credit:NRL Photos
"I know it was a 50-50 call. The thing is three years ago I wouldn't have lost a minute of sleep. But that night was shocking. I didn't sleep that night or the night after. I felt more responsible than I should've been. When you're younger, you look for the big decisions to show everyone you can do it. I'm running around now thinking I just want to get through it."
This is the second time Cecchin has retired from the NRL. He says he means it this time.
He walked away three years ago in the aftermath of the controversial World Cup semi-final between Tonga and England in New Zealand. An avalanche of death threats via social media was picked up by New Zealand and Australian Federal Police.
A fresh start in the UK Super League fell through because of visa problems. Head of football Graham Annesley enticed him back to the NRL but in the past two seasons he has been left out of finals matches.
Cecchin couldn't sleep after a 50-50 call in the round 22 match between Cronulla and Newcastle. Credit:NRL Photos
This weekend's fixture is likely to be Cecchin's last unless a more preferred referee suffers an injury or makes a howler.
"When you feel like you're just making up the numbers, week after week, it gets tricky," he said. "It's hard to stay up when you don't have the carrot of the big games like you once did. For the last year and a half, I've been trying to hold on to my reputation with the players and coaches. It wasn't to be in the grand final or State of Origin, as it has been in the past. It's important for me to be remembered by players and coaches as I am now."
He's leaving the game at a time when the scrutiny has never been so intense on match officials.
Part of the heavy breach notice slapped on the Roosters on Monday related to comments directed towards Cecchin, who was the standby referee on the sideline, after Souths forward Liam Knight was put on report for a hip-drop tackle on rival prop Sio Taukeiaho.
Cecchin refused to comment on the Roosters' behaviour but agreed the job of refereeing had become infinitely harder since his NRL debut in 2001.
"The game is way more technical," he said. "The difficulty now is the contradiction between what the game wants from the referee and what it expects. On one hand, they want extreme accuracy [scrutinised by] nine cameras and super-slo-mo. But they also don't want the game to be decided by a referee unless he absolutely must.
"If you want the referee to be black-and-white, that's easy to officiate. We can be robots and blow 30 penalties. When we don't referee like that, the game is great entertainment. Do we let things flow and become less accurate, but at the same time be fair? That's the art of refereeing. That's what most people want."
Channel Nine analysts Andrew Johns and Brad Fittler are baffled Cecchin is on the outer with referee bosses, both claiming he has a better "feel" than most.
"He's the best referee," Johns said. "He referees exactly the way the game should be refereed. He doesn't over-referee, he knows when to blow a penalty, when to restart a set, how to converse with the players."
Cecchin also isn't easily conned. With seven minutes remaining in the first half of the Penrith-Tigers match on Sunday, Panthers five-eighth Jarome Luai jumped over a Tigers defender, off the mark and then knocked on playing the ball.
"Come on, Cech!" Fittler boomed in commentary. "Sort them out!"
Cecchin sorted it out by ruling a Luai knock on.
"He makes some errors, but they all do," Fittler said. "Cech has the best feel for the game out of all of them."
That's the problem with modern-day refereeing: Cecchin's bosses judge whistleblowers via spreadsheet, not on whether the game has flowed and the referee has become a silent bystander.
In 2003, then referees boss Robert Finch told Cecchin he'd never make it because he was too pedantic. He ran the line for three years, observing the likes of Bill Harrigan and Tim Mander.
"I learned it wasn't about being accurate, it was about stepping into the game when it was appropriate," he said. "And stepping out when appropriate. I had more respect for the game than worrying about myself."
Fittler says Cecchin became a more confident referee after he came out publicly in 2012 as gay.
"I think so," Cecchin said. "Before then, a chunk of my melon had apprehension about what people would think. The same way you have with your family and friends before coming out."
Cecchin has refereed 370 NRL matches (570 in total including games as a touch judge and video referee). He officiated three grand finals, four Origins and 13 Tests.
His legacy?
"I was the first to shake hands with players after game," he said. "Todd Greenberg saw it and now every referee does it."
Andrew Webster is Chief Sports Writer of The Sydney Morning Herald.Connect via Facebook or email.


Two types of defects normally occur in ultrasonically consolidated parts: (i) Defects that occur between mating foils in successive layers ("type 1" defects) and (ii) defects that occur within a layer between two foils laid side-by-side ("type 2" defects). While some success has been achieved in minimizing type 1 defects, type 2 defects, however, have been given very little attention. Both types of defects are undesirable and should be minimized if ultrasonically consolidated parts are to be used in structural applications. This work describes an investigation of how to minimize type 2 defects in ultrasonically consolidated parts. According to our hypothesis, a foil being deposited must overlap the adjacent deposited foil by an optimum amount to ensure a defect-free joint between the two foils. Transverse tensile specimens were fabricated with various amounts of foil overlap (by changing the foil width setting) to test this hypothesis. Metallographic and fractographic studies showed a clear correlation between foil overlap, defect incidence, and tensile strength. It was found that a foil width setting of 23.81 mm helps minimize type 2 defects in ultrasonically consolidated Al 3003 parts using standard foils of 23.88 mm (equivalent to 0.94 in.) nominal width.
Janaki Ram, G. D., Yang, Y., and Stucker, B. E., 2006, "Effect of Process Parameters on Bond Formation During Ultrasonic Consolidation of Aluminum Alloy 3003," J. Manuf. Syst., 25 (3), pp. 221–238.
Wright, D. R., 2003, "Ultrasonic Consolidation of Aluminum Tooling," Advanced Materials & Processes, 161 (1), pp. 64–65.
Kong, C. Y., 2005, "Investigation of Ultrasonic Consolidation for Embedding Active/Passive Fibers in Aluminum Matrices," Ph.D. thesis, Loughborough University, Loughborough, UK.
Siggard, E. J., Madhusoodanan, A. S., Stucker, B., and Eames, B., 2006, "Structurally Embedded Electrical Systems Using Ultrasonic Consolidation (UC)," "Proceedings of the 17th Solid Freeform Fabrication Symposium", Austin, TX, Aug. 14–16.
Obielodan JO, Ram G, Stucker BE, Taggart DG. Minimizing Defects Between Adjacent Foils in Ultrasonically Consolidated Parts. ASME. J. Eng. Mater. Technol. 2009;132(1):011006-011006-8. doi:10.1115/1.3184033.


text:
meyoke.com
buy online toradol coupons no prescription
Nioh 2 – The Complete Edition Preview: Everything Hurts (And That's The Point)
Balan Wonderland Demo Arriving Next Week
Nexplay Esports Signs Wild Rift Roster in the Philippines
amoxicillin uti prophylaxis dose pediatric
Home » News » UK Video Game Industry Generated £4.2 Billion In Revenue In 2020
UK Video Game Industry Generated £4.2 Billion In Revenue In 2020
Video game sales broke the £4 billion mark in the UK for the first time in 2020, outdoing the music and video industries in the process.
In the grand scheme of things, 2020 will go down as a year to forget for a lot of people. However, for gamers and the video game industry, there was a lot to celebrate. A new generation of consoles was ushered in, and it was the toughest year for a while to pick just one game of the year. Titles like Animal Crossing: New Horizons and Final Fantasy 7 Remake are not ones that will be left in 2020 and forgotten forever, that's for sure.
Those games and so many more were not only played by hardened gamers but also new and casual players looking for something to fill some newfound free time. That has been reflected in the revenue generated by the video game industry in the UK last year. According to ERA, Brits spent more than £4.2 billion ($5.7 billion) on video games last year.
Not only is that a 14.5% increase on what was spent on gaming in 2019, but it's the first time the industry has ever broken the £4 billion in the UK. It's also plain to see from the numbers provided that more people than ever turned to digital sales thanks to being locked down for most of the year. £3.6 billion of that revenue came in the form of people gaming digitally rather than purchasing physical media.
The already impressive number looks even better when its compared to the same figures for the music and video industries. While both also experienced jumps in revenue in 2020, the music business registered a little more than £1.5 billion in revenue, while the video industry more than doubled that at a little short of £3.3 billion. However, no matter which way you slice it, video games stand tall.
Despite what many people might think this is nothing new. Even before the pandemic people were spending far more in the UK on video games than they were on video subscriptions and music downloads. With £3.68 billion in revenue in 2019, video games stood tall then too. The next time someone tells you gaming is a niche interest, bust out the whiteboard and show them some of these numbers.
NEXT: Halo Multiplayer Announcer Jeff Steitzer Recites Iconic Voice Lines From "Slayer" To "Killionaire"
Josh has been gaming for as long as he can remember. That love began with a mild childhood addiction to the Sega Genesis, or Mega Drive since he lives in the UK. Back then, Sonic 2 quickly became his favorite game and as you might have guessed from his picture, the franchise has remained close to his heart ever since. Nowadays, he splits his time between his PS4 and his Switch and spends far too much time playing Fortnite. If you're a fan of gaming, wrestling, and soccer, give him a follow on Twitter @BristolBeadz.
Eye of the Temple Reminds You How Amazing Room-Scale VR Is, Demo Available Now
Amazon Driver Fired After Birthday PS5 Goes Missing
Yu-Gi-Oh!: The 15 Most Powerful Trap Cards, Ranked
Watch Today's PS5 Price And Release Date Reveal Here
Watch Ubisoft Forward With Game Informer
Best PS Plus Amazon Prime Day 2020 Deals: What To Expect
Mario Kart Live: Home Circuit Lets You Play Mario Kart In Real Life
Halo Multiplayer Announcer Jeff Steitzer Recites Iconic Voice Lines From "Slayer" To "Killionaire"
cheap herbal soma coupon no prescription
7 Affordable Things That Make You Feel Like A Superstar
eNASCAR Heat Pro League goes green on REV TV Canada
Free Games Available To Download Now (Nintendo Switch, Xbox One, PS4, PC)
Using Software to Comply With DOT Regulations
This Jurassic Park Toy Has Already Won Comic-Con At Home
Pokemon Isle Of Armor: Where To Find Max Mushrooms And Teach Pokemon To Gigantamax
Copyright © 2019 - 2021 meyoke.com.